PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Daniel P PetrylakNicholas J VogelzangKamal ChattaMark T FlemingDavid C SmithLeonard J ApplemanArif HussainManuel ModianoParminder SinghScott T TagawaIra GoreEdward F McClayAnthony E MegaA Oliver SartorBradley SomerRaymond WadlowNeal D ShoreWilliam C OlsonNancy StamblerVincent A DiPippoRobert J IsraelPublished in: The Prostate (2019)
PSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment-related AEs included neutropenia and neuropathy.
Keyphrases
- open label
- prostate cancer
- pet ct
- pet imaging
- phase ii
- clinical trial
- diffusion weighted imaging
- phase ii study
- diffusion weighted
- phase iii
- combination therapy
- squamous cell carcinoma
- multiple sclerosis
- small cell lung cancer
- study protocol
- radical prostatectomy
- randomized controlled trial
- magnetic resonance imaging
- circulating tumor cells
- contrast enhanced
- magnetic resonance
- circulating tumor